ライフサイエンスコーパス: Clostridium difficile infection

1 mycin antibiotic treatment and opportunistic Clostridium difficile infection.

2 contributes to the pathology observed during Clostridium difficile infection.

3 idian Bioscience, Inc.) for the diagnosis of Clostridium difficile infection.

4 rectal procedures without increased risk of Clostridium difficile infection.

5 bleed, ventilator-associated pneumonia, and Clostridium difficile infection.

6 a transplantation for treatment of recurrent Clostridium difficile infection.

7 those at high risk of complications such as Clostridium difficile infection.

8 onia, ICU mortality, ICU length of stay, and Clostridium difficile infection.

9 ) in an investigation of the transmission of Clostridium difficile infection.

10 n of outbreaks is crucial for the control of Clostridium difficile infection.

11 n was recently approved for the treatment of Clostridium difficile infection.

12 aboratories from utilizing real-time PCR for Clostridium difficile infection.

13 ce, severity, and high rate of recurrence of Clostridium difficile infection.

14 mples for CCCA did not increase detection of Clostridium difficile infection.

15 G II plays in the rabbit ileal-loop model of Clostridium difficile infection.

16 the responses of luminal epithelial cells to Clostridium difficile infection.

17 ntestinal symptoms, rash, kidney injury, and Clostridium difficile infection.

18 idity, development of ileus, reoperation and Clostridium difficile infection.

19 xolidinone antibiotic developed for treating Clostridium difficile infection.

20 nsecutive, evaluable patients with recurrent Clostridium difficile infection.

21 and fidaxomicin are therapies of choice for Clostridium difficile infection.

22 ns about promoting antibiotic resistance and Clostridium difficile infection.

23 , ventilator-associated pneumonia (VAP), and Clostridium difficile infections.

24 antimicrobial use and adverse events such as Clostridium difficile infections.

25 r understanding the changing epidemiology of Clostridium difficile infections.

26 zole: 2), and one patient was diagnosed with Clostridium difficile infection (0 vs 1).

27 ently encountered infectious etiologies were Clostridium difficile infection (13.3% and 11.8%, respec

28 Clostridium difficile infection after LT was associated

29 s in Ahrr(-/-) mice caused susceptibility to Clostridium difficile infection and dextran sodium-sulfa

30 ts it has been successfully used in cases of Clostridium difficile infection and IBD, although contro

31 We also assessed rates of Clostridium difficile infection and potential allergic r

32 al microbiota transplantation to face severe Clostridium difficile infections and to perform decoloni

33 ated charges for inflammatory bowel disease, Clostridium difficile infection, and chronic liver disea

34 with outcomes (antibiotic-days, incidence of Clostridium difficile infection, and in-hospital mortali

35 numbers of Staphylococcus aureus bacteremia, Clostridium difficile infection, and vancomycin-resistan

36 han 9000 nosocomial infections, 1000 to 5000 Clostridium difficile infections, and 2 to 6 cases of an

37 ctors affecting a person's susceptibility to Clostridium difficile infection are well-understood, lit

38 The symptoms of Clostridium difficile infections are caused by two exoto

39 tic withdrawal regimen may resolve recurrent Clostridium difficile infection as effectively as fecal

40 sistently toxin-negative patients tested for Clostridium difficile infection between February 1998 an

41 We identified 12 patients with Clostridium difficile infection between July 2011 and Ma

42 s is not observed in subjects with recurrent Clostridium difficile infection but is observed in the s

43 rded as the primary virulence determinant in Clostridium difficile infection, but naturally occurring

44 ffective in treating relapsing or refractory Clostridium difficile infection, but practical barriers

45 cottish government issued a target to reduce Clostridium difficile infection by 30% in 2 years.

46 For 139 patients tested for Clostridium difficile infection by polymerase chain reac

47 Variations in testing for Clostridium difficile infection can hinder patients' car

48 Clostridium difficile infection can result in asymptomat

49 Clostridium difficile infection causes severe complicati

50 The incidence of Clostridium difficile infection (CDI) and associated mor

51 plification tests (NAATs) do not distinguish Clostridium difficile infection (CDI) and asymptomatic C

52 Isolates obtained from patients with Clostridium difficile infection (CDI) and colonization i

53 e advances in the diagnosis and treatment of Clostridium difficile infection (CDI) and prevention eff

54 Nonsevere Clostridium difficile infection (CDI) and severe CDI, wh

55 n to be noninferior to vancomycin for curing Clostridium difficile infection (CDI) and superior for r

56 f reduced response to standard therapies for Clostridium difficile infection (CDI) and the risk for r

57 s of Staphylococcus aureus bacteremia (SAB), Clostridium difficile infection (CDI) and vancomycin-res

58 Obesity and Clostridium difficile infection (CDI) are both related t

59 Candidemia and Clostridium difficile infection (CDI) are important heal

60 es suggest that most cases of hospital-onset Clostridium difficile infection (CDI) are unrelated to o

61 methods may underestimate the true burden of Clostridium difficile infection (CDI) because they fail

62 Prevention and management of Clostridium difficile infection (CDI) can be improved by

63 Clostridium difficile infection (CDI) can cause a wide r

64 Clostridium difficile infection (CDI) can cause severe d

65 Clostridium difficile infection (CDI) causes nearly half

66 tic increase in morbidity and mortality from Clostridium difficile infection (CDI) due to the recent

67 The dramatic changes in the epidemiology of Clostridium difficile infection (CDI) during recent year

68 Little is known about pediatric Clostridium difficile infection (CDI) epidemiology.

69 Isolates from consecutive Clostridium difficile infection (CDI) fecal samples unde

70 Clostridium difficile infection (CDI) following antibiot

71 Recurrent or refractory Clostridium difficile infection (CDI) has become an incr

72 Clostridium difficile infection (CDI) has become one of

73 Research and innovation around Clostridium difficile infection (CDI) has been a multidi

74 dences of antibiotic-associated diarrhea and Clostridium difficile infection (CDI) has been demonstra

75 The incidence of Clostridium difficile infection (CDI) has been increasin

76 icrobiota transplantation (FMT) in recurrent Clostridium difficile infection (CDI) has been limited t

77 igh sensitivity of PCR assays for diagnosing Clostridium difficile infection (CDI) has greatly reduce

78 splantation (FMT) as treatment for recurrent Clostridium difficile infection (CDI) has increased rapi

79 osing to, or modulating disease severity in, Clostridium difficile infection (CDI) has not been inves

80 The incidence of Clostridium difficile infection (CDI) has risen almost 3

81 The incidence of Clostridium difficile infection (CDI) has risen dramatic

82 Patients with recurrent Clostridium difficile infection (CDI) have a >/=60% risk

83 The incidence and severity of Clostridium difficile infection (CDI) have increased wor

84 Since 2000, the incidence and severity of Clostridium difficile infection (CDI) have increased.

85 The currently available diagnostics for Clostridium difficile infection (CDI) have major limitat

86 id suppression medication is associated with Clostridium difficile infection (CDI) in adults and is i

87 ent approved by the FDA for the treatment of Clostridium difficile infection (CDI) in adults over the

88 dies on risk factors for and transmission of Clostridium difficile infection (CDI) in China have been

89 of revised clinical practice guidelines for Clostridium difficile infection (CDI) in February 2018.

90 This article defines the risk factors for Clostridium difficile infection (CDI) in hospitalized ch

91 Rates and severity of Clostridium difficile infection (CDI) in hospitals in No

92 ) is highly effective for treating recurrent Clostridium difficile infection (CDI) in observational s

93 The increased incidence and severity of Clostridium difficile infection (CDI) in older adults (a

94 e clinical and laboratory characteristics of Clostridium difficile infection (CDI) in patients with d

95 e an appropriate therapeutic option for mild Clostridium difficile infection (CDI) in select patients

96 Clostridium difficile infection (CDI) incidence has incr

97 and influenza are associated with nosocomial Clostridium difficile infection (CDI) incidence, but the

98 Marked increases in Clostridium difficile infection (CDI) incidence, driven

99 Clostridium difficile infection (CDI) is a common and in

100 Clostridium difficile infection (CDI) is a common compli

101 Clostridium difficile infection (CDI) is a debilitating

102 Clostridium difficile infection (CDI) is a frequent comp

103 Clostridium difficile infection (CDI) is a growing conce

104 Clostridium difficile infection (CDI) is a leading cause

105 Clostridium difficile infection (CDI) is a leading cause

106 Clostridium difficile infection (CDI) is a leading cause

107 Clostridium difficile infection (CDI) is a leading cause

108 Clostridium difficile infection (CDI) is a major burden

109 Clostridium difficile infection (CDI) is a major cause o

110 Clostridium difficile infection (CDI) is a major nosocom

111 Clostridium difficile infection (CDI) is a serious compl

112 Prevention of recurrent Clostridium difficile infection (CDI) is a substantial t

113 Clostridium difficile infection (CDI) is an important ca

114 Clostridium difficile infection (CDI) is an important ho

115 Clostridium difficile infection (CDI) is associated with

116 Clostridium difficile infection (CDI) is associated with

117 Clostridium difficile infection (CDI) is common after li

118 Clostridium difficile infection (CDI) is facilitated by

119 Mortality among patients with Clostridium difficile infection (CDI) is high.

120 The incidence of Clostridium difficile infection (CDI) is increasing, eve

121 Clostridium difficile infection (CDI) is mediated by act

122 Clostridium difficile infection (CDI) is mediated by two

123 mal therapy for critically ill patients with Clostridium difficile infection (CDI) is not known.

124 f fecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) is not well-known.

125 Recurrent Clostridium difficile infection (CDI) is of particular c

126 Clostridium difficile infection (CDI) is one of the most

127 Clostridium difficile infection (CDI) is the leading cau

128 Clostridium difficile infection (CDI) is the leading hea

129 Clostridium difficile infection (CDI) is the most common

130 Clostridium difficile infection (CDI) is the most common

131 Clostridium difficile infection (CDI) is the number one

132 The success of FMT in curing Clostridium difficile infection (CDI) is well establishe

133 Recurrence of Clostridium difficile infection (CDI) occurs in approxim

134 Symptomatic recurrence of Clostridium difficile infection (CDI) occurs in approxim

135 Recurrent Clostridium difficile infection (CDI) occurs in up to 35

136 Patients with suspected Clostridium difficile infection (CDI) often receive empi

137 The impact of Clostridium difficile infection (CDI) on healthcare is b

138 gel electrophoresis type 1 (NAP1) strain in Clostridium difficile infection (CDI) outcome.

139 Managing recurrent Clostridium difficile infection (CDI) presents a signifi

140 Clostridium difficile infection (CDI) ranges from asympt

141 Variation in Clostridium difficile infection (CDI) rates between heal

142 rganism bloodstream infection (MDRO-BSI) and Clostridium difficile infection (CDI) rates in the 12 mo

143 This study analyzes and reports Clostridium difficile infection (CDI) rates, risk factor

144 innate immune response to the resolution of Clostridium difficile infection (CDI) remains incomplete

145 Clostridium difficile infection (CDI) represents an impo

146 Clostridium difficile infection (CDI) represents the mos

147 Clostridium difficile infection (CDI) results in toxin-i

148 Clostridium difficile infection (CDI) seems to be changi

149 Most Clostridium difficile infection (CDI) surveillance progr

150 of anaerobic microbiota during treatment of Clostridium difficile infection (CDI) than vancomycin an

151 crobiota transplant (FMT) is recommended for Clostridium difficile infection (CDI) treatment; however

152 Treatment of recurrent Clostridium difficile infection (CDI) with antibiotics l

153 Recurrent Clostridium difficile infection (CDI) with poor response

154 are few high-quality studies of the costs of Clostridium difficile infection (CDI), and the majority

155 iable option for the treatment of refractory Clostridium difficile infection (CDI), and, more recentl

156 for the efficacy of probiotics in preventing Clostridium difficile infection (CDI), but guidelines do

157 (FT) is a promising treatment for recurrent Clostridium difficile infection (CDI), but its true effe

158 to increase the risk of community-associated Clostridium difficile infection (CDI), but the associati

159 polymorphism rs4073/-251T >A predisposes to Clostridium difficile infection (CDI), but this associat

160 catheter-associated urinary tract infection, Clostridium difficile infection (CDI), central line-asso

161 oratory tests are available for diagnosis of Clostridium difficile infection (CDI), delays in complet

162 effective alternative therapy for recurrent Clostridium difficile infection (CDI), is infrequently u

163 Unfortunately, the rise of Clostridium difficile infection (CDI), particularly in e

164 During treatment of Clostridium difficile infection (CDI), patterns of patho

165 Clostridium difficile infection (CDI), the most common h

166 es have evaluated risk factors for recurrent Clostridium difficile infection (CDI), the vast majority

167 ens, including acute kidney injury (AKI) and Clostridium difficile infection (CDI), were also conside

168 nts, including acute kidney injury (AKI) and Clostridium difficile infection (CDI).

169 is a highly effective therapy for recurrent Clostridium difficile infection (CDI).

170 ease states, and the prototypical example is Clostridium difficile infection (CDI).

171 he gastrointestinal microbiome to facilitate Clostridium difficile infection (CDI).

172 s (NAATs) as the primary diagnostic test for Clostridium difficile infection (CDI).

173 increasingly being adopted for diagnosis of Clostridium difficile infection (CDI).

174 nd multitest algorithms for the diagnosis of Clostridium difficile infection (CDI).

175 on approved fidaxomicin for the treatment of Clostridium difficile infection (CDI).

176 pt of antibiotics is a major risk factor for Clostridium difficile infection (CDI).

177 recently been approved for the treatment of Clostridium difficile infection (CDI).

178 mg twice per day for 10 days as treatment of Clostridium difficile infection (CDI).

179 collected from patients suspected of having Clostridium difficile infection (CDI).

180 tablished prognostic marker in patients with Clostridium difficile infection (CDI).

181 seases (IBD), and antibiotic-related such as clostridium difficile infection (CDI).

182 peutic effects of dietary supplementation on Clostridium difficile infection (CDI).

183 considered important for protection against Clostridium difficile infection (CDI).

184 is a highly effective therapy for recurrent Clostridium difficile infection (CDI).

185 -Counterpoint on the laboratory diagnosis of Clostridium difficile infection (CDI).

186 an transplantation (Tx) is a risk factor for Clostridium difficile infection (CDI).

187 rope and the United States for patients with Clostridium difficile infection (CDI).

188 e to severe disease and treatment failure in Clostridium difficile infection (CDI).

189 Clostridium difficile infections (CDI) are a growing con

190 Community-onset Clostridium difficile infections (CDI) are increasingly

191 Renewed interest in Clostridium difficile infections (CDI) is stimulating re

192 n to form the vegetative cells that initiate Clostridium difficile infections (CDI).

193 ic, is an investigational drug indicated for Clostridium difficile infections (CDI).

194 trum antibiotic approved for Clostridioides (Clostridium) difficile infection (CDI) in adults, is ass

195 Clostridioides (formerly Clostridium) difficile infection (CDI) is associated wit

196 is and treatment of Clostridioides (formerly Clostridium) difficile infection (CDI).

197 ed hospitalization, and hospitalization with Clostridium difficile infection [CDI]) were associated w

198 BACKGROUND & AIMS: Studies of Clostridium difficile infections (CDIs) among individual

199 Clostridium difficile infections (CDIs) are a growing he

200 d dysbiosis is a key predisposing factor for Clostridium difficile infections (CDIs), which cause int

201 (IRR 0.79; 95% CI, 0.67-0.92; P = .004) and Clostridium difficile infections (CDIs; IRR 0.46; 95% CI

202 The diagnosis of Clostridium difficile infection continues to be a challe

203 viously used to cure patients with recurrent Clostridium difficile infection, could also protect agai

204 n-resistant Staphylococcus aureus (MRSA) and Clostridium difficile infections declined across the UK

205 biotic-based strategies for the treatment of Clostridium difficile infections disrupt indigenous micr

206 currently used for diarrhea associated with Clostridium difficile infection, effectively resensitize

207 The epidemic of Clostridium difficile infection fueled by new virulent s

208 The gut microbiota in recurrent Clostridium difficile infection had lower density and re

209 den of antimicrobial-resistant organisms and Clostridium difficile infections, halting unnecessary an

210 The incidence of Clostridium difficile infection has increased among chil

211 Clostridium difficile infection has increased in inciden

212 The prevalence of Clostridium difficile infections has increased due to th

213 Hospitalizations and mortality from Clostridium difficile infection have doubled in the last

214 Numbers of Clostridium difficile infections have increased worldwid

215 The global prevalence of severe Clostridium difficile infection highlights the profound

216 h care-onset health care facility-associated Clostridium difficile infection (HO-CDI) is overdiagnose

217 actam (PIP/TAZO) shortage and hospital-onset Clostridium difficile infection (HO-CDI) risk in 88 US m

218 vancin was more effective than vancomycin in Clostridium difficile infection in hamsters.

219 been successfully applied to treat recurrent Clostridium difficile infection in humans, but a precise

220 Clostridium difficile infection in LT recipients was ass

221 We compared rates of recurrent Clostridium difficile infection in patients receiving or

222 The detection and diagnosis of Clostridium difficile infection in pediatric populations

223 recognition of several serious outbreaks of Clostridium difficile infection in the industrialized wo

224 The magnitude and scope of Clostridium difficile infection in the United States con

225 The occurrence of Clostridium difficile infections in patients that do not

226 antations for different disorders, including Clostridium difficile infection, irritable bowel syndrom

227 Colitis caused by Clostridium difficile infection is a growing cause of hu

228 Clostridium difficile infection is a growing problem in

229 Clostridium difficile infection is a leading cause of an

230 common misconceptions lead to misdiagnosis: Clostridium difficile infection is a possibility when th

231 Clostridium difficile infection is a relatively common n

232 Clostridium difficile infection is a serious and highly

233 Clostridium difficile infection is almost unrecognized i

234 eudomembranous enterocolitis associated with Clostridium difficile infection is an important cause of

235 Clostridium difficile infection is an increasing burden

236 om recent experiments on antibiotic-mediated Clostridium difficile infection is analyzed to quantify

237 Clostridium difficile infection is associated with broad

238 Disease associated with Clostridium difficile infection is caused by the actions

239 Targeting Clostridium difficile infection is challenging because t

240 Diagnosis of Clostridium difficile infection is controversial because

241 Recurrent Clostridium difficile infection is difficult to treat, a

242 Clostridium difficile infection is increasing in inciden

243 Colonic inflammation in Clostridium difficile infection is mediated by released

244 Their use as probiotics for prevention of Clostridium difficile infection is prevalent among consu

245 Clostridium difficile infection is the leading cause of

246 Clostridium difficile infection is the leading cause of

247 Clostridium difficile infection is the leading cause of

248 Clostridium difficile infection is the main cause of hea

249 Clostridium difficile infection is the most common cause

250 Clostridium difficile infection is the most common healt

251 It has been thought that Clostridium difficile infection is transmitted predomina

252 Of most import is the realization that Clostridium difficile infection is ubiquitous and must b

253 The control of Clostridium difficile infections is an international cli

254 or-associated complication or pneumonia, and Clostridium difficile infection; minor outcomes included

255 1), and grade 3 diarrhea in the presence of Clostridium difficile infection (n = 1).

256 mine whether the reductions in recurrence of Clostridium difficile infection observed with fidaxomici

257 Clostridium difficile infection occurred in 27 (14%) of

258 pment for therapy of systemic infections and Clostridium difficile infection of the gastrointestinal

259 Clostridium difficile infection often occurred soon afte

260 reports found addressed the use of FMTs for Clostridium difficile infection or inflammatory bowel di

261 osure (OR 3.24; 95% CI, 2.99-3.52), and late Clostridium difficile infection (OR 1.60; 95% CI, 1.37-1

262 for the same infection, acute kidney injury, Clostridium difficile infection, or drug-related adverse

263 riptions) ADRs, with Clostridiodes (formerly Clostridium) difficile infections pivotal to its ADR pro

264 with their use including increased risk for Clostridium difficile infection, pneumonia, and fracture

265 dmission rates, central venous catheter use, Clostridium difficile infection rates, and hospital leng

266 8, P = 0.04, I = 36%), with no difference in Clostridium difficile infection rates.

267 Recurrent Clostridium difficile infection (RCDI) is associated wit

268 utic modality for the treatment of recurrent Clostridium difficile infection (RCDI).

269 tinal flora with resultant cure of recurrent Clostridium difficile infection (RCDI).

270 T) is recommended for treatment of recurrent Clostridium difficile infection (rCDI).

271 ast 50 years for the treatment of refractory Clostridium difficile infections (RCDIs) in adults, it h

272 py, and frequency of complications including Clostridium difficile infection, readmission, and all-ca

273 e-level association test of the reduction in Clostridium difficile infection recurrence in patients t

274 le in developing the IDSA/SHEA guidelines on Clostridium difficile infection (see Wilcox and Planche'

275 Clostridium difficile infection should be ruled out, as

276 treatment of portal systemic encephalopathy, Clostridium difficile infection, small bowel intestinal

277 Whereas many antibiotics increase risk of Clostridium difficile infection through dysbiosis, epide

278 treated population, the overall incidence of Clostridium difficile infection was 1.7% in the ertapene

279 Rates of nosocomial Clostridium difficile infection were compared by using i

280 as oral non-systemic antibacterial drugs for Clostridium difficile infections were active against pat

281 ation (FMT) is effective in the treatment of Clostridium difficile infection, where efficacy correlat

282 fective for treating patients with recurrent Clostridium difficile infection who are left with few cl

283 cohort of 109 subjects treated for recurrent Clostridium difficile infection with fecal microbiota tr

284 t serious cephalosporin-associated ADRs were Clostridium difficile infection within 90 days (0.91%),

285 acious and inexpensive therapy for recurrent Clostridium difficile infection, yet its safety is thoug